Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW211026 ointment in actinic keratosis
NCT07318675Phase 1Recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in actinic keratosis (AK) comparing HW211026 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
HW211026
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT07318675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318675.